Skip to main content
. 2022 Jun 7;23(12):6380. doi: 10.3390/ijms23126380

Figure 4.

Figure 4

Central CX3CL1 does not reduce weight gain and food intake in mice treated with MC3R/MC4R antagonist. (A) Time scale of the experimental approach used for acute i.c.v. administration of SHU9119 and CX3CL1. (B,C) Average of cumulative 24 h food intake (A) and body weight gain (B) in mice treated with saline (Sal) or SHU9119 i.c.v. and 30 min later with Sal or CX3CL1 i.c.v. Data are presented as mean ± SEM of at least 5 animals per group. * p < 0.05. (D) Time scale for chronic i.c.v. administration of SHU9119 in mice previously subjected to hypothalamic viral microinjection of AAV–GFP and AAV–CX3CL1. (E,F) Body weight gain (E) and total food intake (F) measured in mice with hypothalamic overexpression of CX3CL1-s or GFP control that received SHU9119 i.c.v. infusion over 2 weeks (compare with Figure 1D). Data are presented as mean ± SEM of 10 animals per group. * p < 0.05.